VistaGen Therapeutics

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell VTGN and other ETFs, options, and stocks.

About VTGN

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy. 

CEO
Shawn K. Singh
CEOShawn K. Singh
Employees
36
Employees36
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1998
Founded1998
Employees
36
Employees36

VTGN Key Statistics

Market cap
25.13M
Market cap25.13M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
2.96M
Average volume2.96M
High today
$0.1369
High today$0.1369
Low today
$0.12
Low today$0.12
Open price
$0.132
Open price$0.132
Volume
2.31M
Volume2.31M
52 Week high
$2.11
52 Week high$2.11
52 Week low
$0.0768
52 Week low$0.0768

VTGN Earnings

-$0.30
-$0.20
-$0.10
$0.00
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Q1 FY23
Q2 FY23
Q3 FY23
Estimated
per share
Estimated per share
Actual
Expected Feb 9, After Hours
ActualExpected Feb 9, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.